We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Alto Neuroscience, Inc. (ANRO - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Alto Neuroscience, Inc. is a member of the Medical sector. This group includes 951 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Alto Neuroscience, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ANRO's full-year earnings has moved 1.9% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, ANRO has returned 168.3% so far this year. Meanwhile, stocks in the Medical group have gained about 5.4% on average. As we can see, Alto Neuroscience, Inc. is performing better than its sector in the calendar year.
Editas Medicine (EDIT - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 100%.
Over the past three months, Editas Medicine's consensus EPS estimate for the current year has increased 0.9%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Alto Neuroscience, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 469 individual stocks and currently sits at #87 in the Zacks Industry Rank. On average, this group has gained an average of 15% so far this year, meaning that ANRO is performing better in terms of year-to-date returns. Editas Medicine is also part of the same industry.
Alto Neuroscience, Inc. and Editas Medicine could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Alto Neuroscience, Inc. (ANRO - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Alto Neuroscience, Inc. is a member of the Medical sector. This group includes 951 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Alto Neuroscience, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ANRO's full-year earnings has moved 1.9% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, ANRO has returned 168.3% so far this year. Meanwhile, stocks in the Medical group have gained about 5.4% on average. As we can see, Alto Neuroscience, Inc. is performing better than its sector in the calendar year.
Editas Medicine (EDIT - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 100%.
Over the past three months, Editas Medicine's consensus EPS estimate for the current year has increased 0.9%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Alto Neuroscience, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 469 individual stocks and currently sits at #87 in the Zacks Industry Rank. On average, this group has gained an average of 15% so far this year, meaning that ANRO is performing better in terms of year-to-date returns. Editas Medicine is also part of the same industry.
Alto Neuroscience, Inc. and Editas Medicine could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.